{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:11:45Z","timestamp":1788941505133,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","award":["IT-72-RG-33\/ISR004983"],"award-info":[{"award-number":["IT-72-RG-33\/ISR004983"]}],"id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bone.2026.117906","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:00:19Z","timestamp":1777046419000},"page":"117906","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation\u00a0+\u00a0enzalutamide\u00a0\u00b1\u00a0zoledronic acid (BonEnza study)"],"prefix":"10.1016","volume":"209","author":[{"given":"I.","family":"Caramella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dalla Volta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Valcamonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bergamini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buffoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Di Meo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zamboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ravanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zamparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bresciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.bone.2026.117906_bb0005","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2026.117906_bb0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2026.117906_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2026.117906_bb0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.bone.2026.117906_bb0025","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","article-title":"Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs","volume":"87","author":"Mittan","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bone.2026.117906_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010113","article-title":"Effect of androgen-deprivation therapy on bone mineral density in patients with prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Kim","year":"2019","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.bone.2026.117906_bb0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2026.117906_bb0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.5432","article-title":"Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer","volume":"5","author":"Suarez-Almazor","year":"2022","journal-title":"JAMA Netw. Open"},{"issue":"15","key":"10.1016\/j.bone.2026.117906_bb0045","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bone.2026.117906_bb0050","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bone.2026.117906_bb0055","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2026.117906_bb0060","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-07568-9","article-title":"Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.bone.2026.117906_bb0065","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.bone.2026.117906_bb0070","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"suppl_2","key":"10.1016\/j.bone.2026.117906_bb0075","first-page":"S954","article-title":"Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons","volume":"34","author":"Jones","year":"2023","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.bone.2026.117906_bb0080","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2026.117906_bb0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.bone.2026.117906_bb0090","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.eururo.2024.05.004","article-title":"Whole-body diffusion-weighted magnetic resonance imaging for assessment of the bone response rate in patients with metastatic hormone-sensitive prostate cancer receiving enzalutamide","volume":"86","author":"Dalla Volta","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bone.2026.117906_bb0095","article-title":"Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial","author":"Dalla Volta","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2026.117906_bb0100","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1007\/s00586-003-0613-0","article-title":"Recognizing and reporting osteoporotic vertebral fractures","volume":"12","author":"Grigoryan","year":"2003","journal-title":"Eur. Spine J."},{"issue":"3","key":"10.1016\/j.bone.2026.117906_bb0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/03008916241236279","article-title":"Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey","volume":"110","author":"Valsecchi","year":"2024","journal-title":"Tumori"},{"issue":"10","key":"10.1016\/j.bone.2026.117906_bb0110","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s11912-023-01447-9","article-title":"Role of body composition in the prediction of skeletal fragility induced by hormone deprivation therapies in cancer patients","volume":"25","author":"Dalla Volta","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.bone.2026.117906_bb0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12020-021-02806-x","article-title":"DXA parameters, Trabecular Bone Score (TBS) and Bone Mineral Density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis","volume":"74","author":"Shevroja","year":"2021","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/j.bone.2026.117906_bb0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40618-023-02174-5","article-title":"Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors","volume":"47","author":"Antonini","year":"2024","journal-title":"J. Endocrinol. Investig."},{"issue":"6D","key":"10.1016\/j.bone.2026.117906_bb0125","first-page":"4697","article-title":"Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy. Gruppo Onco Urologico Piemontese (G.O.U.P)","volume":"17","author":"Berruti","year":"1997","journal-title":"Anticancer Res."},{"issue":"9768","key":"10.1016\/j.bone.2026.117906_bb0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.bone.2026.117906_bb0135","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","article-title":"Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents","volume":"22","author":"Lipton","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bone.2026.117906_bb0140","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.euo.2024.01.016","article-title":"Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Jones","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"4","key":"10.1016\/j.bone.2026.117906_bb0145","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10147-025-02711-7","article-title":"Longitudinal assessment of bone mineral density in prostate cancer patients: comparing metastatic and non-metastatic regions","volume":"30","author":"Hara","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bone.2026.117906_bb0150","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1007\/s00198-024-07180-8","article-title":"The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy","volume":"35","author":"van Oostwaard","year":"2024","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2026.117906_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2015.09.020","article-title":"Vertebral fractures: clinical importance and management","volume":"129","author":"Kendler","year":"2016","journal-title":"Am. J. Med."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226001328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226001328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:20:09Z","timestamp":1783059609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226001328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S8756328226001328"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.117906","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation\u00a0+\u00a0enzalutamide\u00a0\u00b1\u00a0zoledronic acid (BonEnza study)","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.117906","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117906"}}